Literature DB >> 16038477

Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes.

M Luisa Rodríguez de la Concepción1, Pilar Yubero, Joan C Domingo, Roser Iglesias, Pere Domingo, Frcancesc Villarroya, Marta Giralt.   

Abstract

OBJECTIVE: Human adipose depots contain remnant brown adipocytes interspersed among white adipocytes, and disturbances of brown with respect to white adipocyte biology have been implicated in highly active antiretroviral therapy (HAART)-induced lipomatosis. Brown adipocytes express the uncoupling protein-1 (UCP1) and contain a large number of mitochondria, potential targets of HAART toxicity. The aim of this study was to evaluate the effects of reverse transcriptase inhibitors (RTIs) on primary brown adipocytes differentiated in culture. DESIGN AND METHODS: We analysed the effects of RTIs, nucleoside analogues (NRTIs: stavudine, zidovudine, didanosine and lamivudine) and non-nucleoside analogues (NNRTIs: nevirapine and efavirenz), on differentiation, mitochondrial biogenesis and gene expression in brown adipocytes.
RESULTS: None of the NRTIs altered brown adipocyte differentiation whereas NNTRIs had differing effects. Efavirenz blocked lipid deposition and expression of adipose marker genes but nevirapine induced lipid accumulation and adipose gene expression, promoted mitochondrial biogenesis and increased UCP1. Stavudine, zidovudine and didanosine reduced mitochondrial DNA (mtDNA) content. However, mitochondrial genome expression was only impaired in didanosine-treated adipocytes. Stavudine, but not zidovudine, induced expression of the mitochondrial transcription factors and this may explain compensatory mechanisms for the depletion of mtDNA by up-regulating mtDNA transcription. Stavudine caused a specific induction of UCP1 gene expression through direct interaction with a retinoic acid-dependent pathway.
CONCLUSIONS: Specific disturbances in brown adipocytes in adipose depots may contribute to HAART-induced lipomatosis. Mitochondrial depletion does not appear to be the only mechanism explaining adverse effects in brown adipocytes because there is evidence of compensatory mechanisms that maintain mtDNA expression, and the expression of the UCP1 gene is specifically altered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16038477

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  6 in total

1.  Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Authors:  Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2011-11-02       Impact factor: 7.045

2.  Physical fitness in children infected with the human immunodeficiency virus: associations with highly active antiretroviral therapy.

Authors:  Gabriel Somarriba; Gabriela Lopez-Mitnik; David A Ludwig; Daniela Neri; Natasha Schaefer; Steven E Lipshultz; Gwendolyn B Scott; Tracie L Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-31       Impact factor: 2.205

3.  Combination of Tenofovir and Emtricitabine with Efavirenz Does Not Moderate Inhibitory Effect of Efavirenz on Mitochondrial Function and Cholesterol Biosynthesis in Human T Lymphoblastoid Cell Line.

Authors:  Min Li; Anuoluwapo Sopeyin; Elijah Paintsil
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

Authors:  Martine Caron; Corinne Vigouroux; Jean-Philippe Bastard; Jacqueline Capeau
Journal:  PPAR Res       Date:  2008-12-30       Impact factor: 4.964

5.  Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers.

Authors:  Sergio Barroso; Constanza Morén; Àlex González-Segura; Neus Riba; Joan A Arnaiz; Marcela Manriquez; Gemina Santana; José L Blanco; María Larousse; Montse Loncà; Elisa de Lazzari; Jaume Llopis; Josep Mallolas; Oscar Miró; Xavier Carné; Jose M Gatell; Glòria Garrabou; Esteban Martínez
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

Review 6.  Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome.

Authors:  P Pérez-Matute; L Pérez-Martínez; J R Blanco; J A Oteo
Journal:  Oxid Med Cell Longev       Date:  2013-07-21       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.